Computational identification of a p38 SAPK-regulated transcription factor network required for tumor cell quiescence

Cancer Research

Volumn 69, Issue 14, 2009, Pages 5664-5672

  Adam, Alejandro P ^b,c   George, Ajish ^a,b   Schewe, Denis ^a,b,d   Bragado, Paloma ^a   Iglesias, Bibiana V ^b,c   Ranganathan, Aparna C ^a,b   Kourtidis, Antonis ^b   Conklin, Douglas S ^b   Aguirre Ghiso, Julio A ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT ALBANY   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC HELIX LOOP HELIX B3 TRANSCRIPTION FACTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN C JUN; PROTEIN FOXM1; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BHLHB3 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; DORMANCY; DOWN REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR CELL; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; BIOLOGY; CHICK EMBRYO; DNA MICROARRAY; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; GENE EXPRESSION PROFILING; GENETICS; IMMUNOBLOTTING; METABOLISM; METHODOLOGY; NEOPLASM; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CHICK EMBRYO; COMPUTATIONAL BIOLOGY; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; HUMANS; IMIDAZOLES; IMMUNOBLOTTING; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-JUN; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67651003108     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3820     Document Type: Article

References (40)

1. Bulavin DV, Fornace AJ, Jr. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 2004;92:95-118.
2. Bulavin DV, Demidov ON, Saito S, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002;31:210-5.
3. Bulavin DV, Phillips C, Nannenga B, et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf ) pathway. Nat Genet 2004;36:343-50.
4. Ventura JJ, Tenbaum S, Perdiguero E, et al. p38α MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 2007; 39:750-8.
5. Hui L, Bakiri L, Mairhorfer A, et al. p38α suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 2007;39:741-9.
6. Junttila MR, Ala-Aho R, Jokilehto T, et al. p38α and p38δ mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 2007;26:5267-79.
7. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003;63:1684-95.
8. Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 2004;64:7336-45.
9. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001;12:863-79.
10. Hickson JA, Huo D, Vander Griend DJ, et al. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res 2006;66: 2264-70.
11. Timofeev O, Lee TY, Bulavin DV. A subtle change in p38 MAPK activity is sufficient to suppress in vivo tumorigenesis. Cell Cycle 2005;4:118-20.
12. Ossowski L, Reich E. Changes in malignant phenotype of a human carcinoma conditioned by growth environment. Cell 1983;33:323-33.
13. Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002;1:445-57.
14. Ranganathan AC, Ojha S, Kourtidis A, Conklin DS, Aguirre-Ghiso JA. Dual function of pancreatic endoplasmic reticulum kinase in tumor cell growth arrest and survival. Cancer Res 2008;68:3260-8.
15. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3: Article3.
16. Tuck DP, Kluger HM, Kluger Y. Characterizing disease states from topological properties of transcriptional regulatory networks. BMC Bioinformatics 2006;7:236.
17. Ferrer-Martinez A, Marotta M, Baldan A, Haro D, Gomez-Foix AM. Chicken ovalbumin upstream promoter-transcription factor I represses the transcriptional activity of the human muscle glycogen phosphorylase promoter in C2C12 cells. Biochim Biophys Acta 2004;1678:157-62.
18. Azmi S, Ozog A, Taneja R. Sharp-1/DEC2 inhibits skeletal muscle differentiation through repression of myogenic transcription factors. J Biol Chem 2004;279: 52643-52.
19. Kawamoto T, Noshiro M, Furukawa M, et al. Effects of fasting and re-feeding on the expression of Dec1, Per1, and other clock-related genes. J Biochem (Tokyo) 2006;140:401-8.
20. Rohleder N, Langer C, Maus C, et al. Influence of photoperiodic history on clock genes and the circadian pacemaker in the rat retina. Eur J Neurosci 2006;23: 105-11.
21. Falvella FS, Colombo F, Spinola M, et al. BHLHB3: a candidate tumor suppressor in lung cancer. Oncogene 2008;27:3761-4.
22. Toruner GA, Ulger C, Alkan M, et al. Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. Cancer Genet Cytogenet 2004;154:27-35.
23. Gath HJ, Brakenhoff RH. Minimal residual disease in head and neck cancer. Cancer Metastasis Rev 1999;18: 109-26.
24. Pan Y, Haines DS. Identification of a tumor-derived p53 mutant with novel transactivating selectivity. Oncogene 2000;19:3095-100.
25. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999;147:89-104.
26. Nicolaides NC, Correa I, Casadevall C, et al. The Jun family members, c-Jun and JunD, transactivate the human c-myb promoter via an Ap1-like element. J Biol Chem 1992;267:19665-72.
27. Stepniak E, Ricci R, Eferl R, et al. c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. Genes Dev 2006;20:2306-14.
28. Eferl R, Ricci R, Kenner L, et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 2003;112:181-92.
29. Schreiber M, Kolbus A, Piu F, et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 1999;13:607-19.
30. Schewe DM, Aguirre-Ghiso JA. ATF6α-RhebmTOR signaling promotes survival of dormant tumor cells in vivo. Proc Natl Acad Sci U S A 2008; 105:10519-24.
31. Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 2007;1775:92-102.
32. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
33. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
34. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
35. Bulavin DV, Saito S, Hollander MC, et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999;18:6845-54.
36. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001;8:781-94.
37. Thukral SK, Blain GC, Chang KK, Fields S. Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2. Mol Cell Biol 1994;14:8315-21.
38. Adorno M, Cordenonsi M, Montagner M, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. Cell 2009;137:87-98.
39. Cocolakis E, Lemay S, Ali S, Lebrun JJ. The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem 2001;276:18430-6.
40. Gal A, Sjoblom T, Fedorova L, et al. Sustained TGF β exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene 2008;27: 1218-30.